SOFTOMOTIVE
13.12.2018 10:44:19 CET | Business Wire | Press release
Businesses are still struggling to understand where and how to start Robotic Process Automation (RPA). This was also a key finding of the first-of-a-kind global research by Softomotive into RPA for Growth Companies conducted by KS&R .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005261/en/
“Despite uncertainty about which are the best processes to start automating, conventional wisdom is still typically to start with a big bang approach with high upfront investments associated with software, hardware and consulting, which carries more project risk, is more rigid and is less innovative, “said Marios Stavropoulos, CEO and co-founder of Softomotive, “In whichever currency you work in, it simply does not add up any longer. This has led some of our customers to say that there must be a better way to RPA rather than doing the same old thing. It is a time for a People1st approach to managing process automation to drive the next productivity revolution”.
Softomotive’s People1st Approach to RPA means putting People before Robots. People or “Citizen Developers” have the knowledge, skills and understanding to consistently select and develop the best tasks and processes to automate. Only once these have been tested and proven should they be deployed enterprise-wide, in either attended (Bots interacting with humans) or unattended mode (Bots acting independently).
Marios continued “Our People1st approach to RPA, by giving everyone their own digital assistant, places the power firmly into the hands of the people that do the work. This means in a People1st world, everyone is a “Citizen Developer” because they know best what works and what does not. It should not be left to a centralized department like the Center of Excellence (COE) to make this happen.”
The key advantages of adopting a People1st approach to RPA are summarised below:
|
Rationale |
Current, broken approach |
"People 1st" Approach |
|||
| Upfront Investment | High | Low | |||
| Risk | High | Low | |||
| Development Method |
Hybrid |
Agile | |||
| Automation Discovery | Limited | Supercharged | |||
| People Engagement | Low | High | |||
| Scope | COE | Business-Wide |
Source: Softomotive
Marios explained “A brand new business model for managing process automation is required to address our People1st approach which splits into three distinct stages called the 3 I’s. First, is Innovate , then Incubate and finally Implement. Each of these have a number of steps making up a seven step blue print for introducing a People1st approach to RPA.”
Argyris Kaninis, the COO and co-founder of Softomotive added, “Softomotive is the only RPA vendor to offer a desktop version WinAutomation , as well as server-based unattended and attended automation solutions ProcessRobot . These two working together are uniquely qualified to support a People 1st Approach to RPA because the desktop version is easily installed on everyone’s computer to accelerate innovation in process automation from the bottom up”. He continued, “Once the best automations have been filtered, tested and prepared by the COE, they can be scaled as business as usual using our enterprise RPA platform. The transition from one to the other is made easy since both solutions share the same RPA engine.”
ENDS
About Softomotive
Softomotive is a leading worldwide providers of Robotic Process Automation solutions, trusted by more than 8,000 companies worldwide.
Softomotive provides the smoothest RPA journey by allowing you to start small, learn quickly and scale seamlessly. This helps to reduce overall project risk and avoids high up-front costs which can make achieving a positive ROI that much harder.
- WinAutomation is the world’s best desktop automation tool and provides a powerful, robust and easy to use Windows-based platform for building software robots.
- ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, with links to best-of-breed AI technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005261/en/
Contact:
Softomotive Bob Weare, Chief Marketing Officer press@softomotive.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom